These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24155259)

  • 1. Intermolecular interactions and conformation of antibody dimers present in IgG1 biopharmaceuticals.
    Iwura T; Fukuda J; Yamazaki K; Kanamaru S; Arisaka F
    J Biochem; 2014 Jan; 155(1):63-71. PubMed ID: 24155259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.
    Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R
    J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC.
    Lau H; Pace D; Yan B; McGrath T; Smallwood S; Patel K; Park J; Park SS; Latypov RF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Apr; 878(11-12):868-76. PubMed ID: 20206584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folding and oxidation of the antibody domain C(H)3.
    Thies MJ; Talamo F; Mayer M; Bell S; Ruoppolo M; Marino G; Buchner J
    J Mol Biol; 2002 Jun; 319(5):1267-77. PubMed ID: 12079363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folding and self-assembly of herpes simplex virus type 1 thymidine kinase.
    Wurth C; Thomas RM; Folkers G; Scapozza L
    J Mol Biol; 2001 Oct; 313(3):657-70. PubMed ID: 11676546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of two major aggregation pathways in an IgG2 antibody.
    Van Buren N; Rehder D; Gadgil H; Matsumura M; Jacob J
    J Pharm Sci; 2009 Sep; 98(9):3013-30. PubMed ID: 18680168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active dimer of Epratuzumab provides insight into the complex nature of an antibody aggregate.
    Remmele RL; Callahan WJ; Krishnan S; Zhou L; Bondarenko PV; Nichols AC; Kleemann GR; Pipes GD; Park S; Fodor S; Kras E; Brems DN
    J Pharm Sci; 2006 Jan; 95(1):126-45. PubMed ID: 16315222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting.
    Deperalta G; Alvarez M; Bechtel C; Dong K; McDonald R; Ling V
    MAbs; 2013; 5(1):86-101. PubMed ID: 23247543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into dimerization and four-helix bundle formation found by dissection of the dimer interface of the GrpE protein from Escherichia coli.
    Mehl AF; Heskett LD; Jain SS; Demeler B
    Protein Sci; 2003 Jun; 12(6):1205-15. PubMed ID: 12761391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.
    Franey H; Brych SR; Kolvenbach CG; Rajan RS
    Protein Sci; 2010 Sep; 19(9):1601-15. PubMed ID: 20556807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution.
    Chang BS; Beauvais RM; Arakawa T; Narhi LO; Dong A; Aparisio DI; Carpenter JF
    Biophys J; 1996 Dec; 71(6):3399-406. PubMed ID: 8968609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain.
    McAuley A; Jacob J; Kolvenbach CG; Westland K; Lee HJ; Brych SR; Rehder D; Kleemann GR; Brems DN; Matsumura M
    Protein Sci; 2008 Jan; 17(1):95-106. PubMed ID: 18156469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy.
    Lee YC; Boehm MK; Chester KA; Begent RH; Perkins SJ
    J Mol Biol; 2002 Jun; 320(1):107-27. PubMed ID: 12079338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation.
    Brych SR; Gokarn YR; Hultgen H; Stevenson RJ; Rajan R; Matsumura M
    J Pharm Sci; 2010 Feb; 99(2):764-81. PubMed ID: 19691118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2.
    Yang J; Goetze AM; Flynn GC
    Mol Immunol; 2014 Mar; 58(1):108-15. PubMed ID: 24321397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis.
    Gadgil HS; Bondarenko PV; Pipes GD; Dillon TM; Banks D; Abel J; Kleemann GR; Treuheit MJ
    Anal Biochem; 2006 Aug; 355(2):165-74. PubMed ID: 16828048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of IgG1 aggregation in solution.
    Ojala F; Degerman M; Hansen TB; Broberg Hansen E; Nilsson B
    Biotechnol J; 2014 Jun; 9(6):800-4. PubMed ID: 24760776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Changes and Aggregation Mechanisms of Two Different Dimers of an IgG2 Monoclonal Antibody.
    Zhang J; Woods C; He F; Han M; Treuheit MJ; Volkin DB
    Biochemistry; 2018 Sep; 57(37):5466-5479. PubMed ID: 30141909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.
    Plath F; Ringler P; Graff-Meyer A; Stahlberg H; Lauer ME; Rufer AC; Graewert MA; Svergun D; Gellermann G; Finkler C; Stracke JO; Koulov A; Schnaible V
    MAbs; 2016 Jul; 8(5):928-40. PubMed ID: 27031922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.